RU2005138320A - Композиция для поддержания жизнеспособности органов и клеток - Google Patents
Композиция для поддержания жизнеспособности органов и клеток Download PDFInfo
- Publication number
- RU2005138320A RU2005138320A RU2005138320/15A RU2005138320A RU2005138320A RU 2005138320 A RU2005138320 A RU 2005138320A RU 2005138320/15 A RU2005138320/15 A RU 2005138320/15A RU 2005138320 A RU2005138320 A RU 2005138320A RU 2005138320 A RU2005138320 A RU 2005138320A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- acid
- phase composition
- phase
- range
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Claims (34)
1. Двухфазная композиция для обеспечения жизнеспособности клеток, включающая первую фазу, включающую основную питательную среду, и вторую фазу, включающую наночастицы, которые включают внешнее липофильное покрытие и внутренний гидрофильный центр, в которой
а) первая фаза включает физиологически сочетаемые концентрации растворимых или диспергируемых в воде питательных веществ и физиологических солей;
b) наночастицы второй фазы включают липиды, жирные кислоты, стеролы и свободные жирные кислоты; и
с) двухфазная композиция имеет осмотическое давление по меньшей мере примерно 300 мОсмоль/кг.
2. Двухфазная композиция по п.1, в которой двухфазная композиция имеет осмотическое давление в диапазоне примерно 385-425 мОсмоль/кг.
3. Двухфазная композиция по п.1, в которой ее рН составляет от примерно 7,2 до примерно 7,4.
4. Двухфазная композиция по п.1, в которой наночастицы имеют средний диаметр в диапазоне от примерно 100 нм до примерно 300 нм.
5. Двухфазная композиция по п.4, в которой наночастицы имеют средний диаметр в диапазоне от примерно 100 нм до примерно 200 нм.
6. Двухфазная композиция по п.1, дополнительно включающая факторы роста клеток.
7. Двухфазная композиция по п.6, в которой указанные факторы клеточного роста, выбирают из группы, состоящей из факторов роста эпителия или эндотелия, факторов роста эндотелия сосудов, эндотелиальных факторов роста, выделяемых из тромбоцитов, эпителиальных факторов роста, гепатоцитарных факторов роста и их смесей.
8. Двухфазная композиция по п.1, которая включает примерно равные количества первой фазы и второй фазы.
9. Двухфазная композиция по п.1, в которой центральная часть включает свободные жирные кислоты, выбранные из группы, состоящей из олеиновой кислоты, линолевой кислоты, пальмитиновой, стеариновой кислоты, миристиновой кислоты, лауриновой кислоты, эйкозапентаеновой кислоты, докозагексаеновой кислоты и их комбинации.
10. Двухфазная композиция по п.1, в которой наночастица имеет размер частицы в диапазоне от примерно 100 нм до примерно 200 нм.
11. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
12. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
13. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
14. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
15. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
16. Двухфазная композиция по п. 1, которая включает
ДИАПАЗОН
17. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
18. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
19. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
20. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
21. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
22. Двухфазная композиция по п.1, которая включает
ДИАПАЗОН
23. Двухфазная композиция по п.1, в которой указанный внутренний гидрофильный центр содержит раствор или суспензию, включающую компонент, способный связывать и высвобождать кислород.
24. Двухфазная композиция по п.10, в которой компонент, способный связывать и высвобождать кислород, представляет собой гемсодержащий белок.
25. Двухфазная композиция по п.1, в которой указанный внутренний гидрофильный центр содержит биологически активный компонент.
26. Двухфазная композиция по п.25, в которой указанный биологически активный компонент выбирают из группы, состоящей из хемиотерапевтических агентов, белков, пептидов, полипептидов, ферментов и их смесей.
27. Двухфазная композиция по п.25, в которой указанный биологически активный компонент представляет собой ранпирназу.
28. Трехфазная композиция, включающая композицию по п.1, смешанную с композицией, содержащей наночастицу, имеющую внешнее липофильное покрытие и внутренний гидрофильный центр, включающий раствор или суспензию, включающие компонент, способный к связыванию и высвобождению кислорода.
29. Трехфазная композиция по п.28, в которой фрагмент способный связывать и высвобождать кислород, представляет собой гемсодержащий белок.
30. Трехфазная композиция, включающая композицию по п.1, смешанную с композицией, включающей наночастицу, имеющую внешнее липофильное покрытие и внутренний гидрофильный центр, включающий биологически активный компонент.
31. Способ получения двухфазной композиции по п.1, включающий объединение жидкой первой фазы, включающей основную питательную среду, содержащую физиологически приемлемые концентрации растворимых или диспергируемых в воде питательных веществ и физиологических солей, с жидкой второй фазой, содержащей наночастицы, которые включают внешнее липофильное покрытие и внутренний гидрофильный центр, в условиях, достаточных для получения конечной двухфазной композиции, имеющей осмотическое давление по меньшей мере 300 мОсмоль/кг.
32. Способ сохранения клеток или тканей млекопитающего, включающий помещение указанных клеток и указанной ткани в достаточное количество композиции по п.1.
33. Способ сохранения органа млекопитающего ex vivo, включающий помещение органа в достаточное количество композиции по п.1.
34. Способ по п.33, в котором указанный орган выбирают из группы, состоящей из почки, сердца, печени, легкого, кожи, артерии и их функциональных частей.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46920003P | 2003-05-09 | 2003-05-09 | |
US60/469,200 | 2003-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2005138320A true RU2005138320A (ru) | 2006-04-27 |
Family
ID=32991004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005138320/15A RU2005138320A (ru) | 2003-05-09 | 2004-05-07 | Композиция для поддержания жизнеспособности органов и клеток |
Country Status (12)
Country | Link |
---|---|
US (3) | US7604933B2 (ru) |
EP (3) | EP1475434A1 (ru) |
JP (2) | JP5192694B2 (ru) |
KR (1) | KR20060019525A (ru) |
CN (2) | CN1816617B (ru) |
AU (2) | AU2004239310B2 (ru) |
BR (1) | BRPI0410185A (ru) |
CA (2) | CA2523417C (ru) |
MX (1) | MXPA05012070A (ru) |
RU (1) | RU2005138320A (ru) |
WO (2) | WO2004099393A1 (ru) |
ZA (1) | ZA200509760B (ru) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1475434A1 (en) * | 2003-05-09 | 2004-11-10 | Oncoscience AG | Method for storing tumor cells |
US7087369B2 (en) | 2003-12-17 | 2006-08-08 | The Regents Of The University Of California | Cornea preservation medium |
JP2005306749A (ja) * | 2004-04-19 | 2005-11-04 | Kringle Pharma Inc | Hgf含有臓器保存液 |
US8304181B2 (en) | 2004-10-07 | 2012-11-06 | Transmedics, Inc. | Method for ex-vivo organ care and for using lactate as an indication of donor organ status |
CA3178010A1 (en) | 2004-10-07 | 2006-04-20 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US9078428B2 (en) | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
PT2347775T (pt) | 2005-12-13 | 2020-07-14 | The President And Fellows Of Harvard College | Estruturas em andaime para transplante celular |
KR100809046B1 (ko) * | 2006-03-10 | 2008-03-03 | 가톨릭대학교 산학협력단 | 풀루란을 가진 나노자가응집체 및 이의 이용방법 |
EP3103451A1 (en) | 2007-01-12 | 2016-12-14 | University of Maryland, Baltimore | Targetting ncca-atp channel for organ protection following ischemic episode |
AU2008216612B2 (en) * | 2007-02-17 | 2014-12-04 | President And Fellows Of Harvard College | Compositions and method for tissue preservation |
KR100834687B1 (ko) * | 2007-02-21 | 2008-06-02 | 주식회사 엘지생활건강 | 히노키티올 함유 지질 나노 입자 및 그의 제조방법 |
US9457179B2 (en) | 2007-03-20 | 2016-10-04 | Transmedics, Inc. | Systems for monitoring and applying electrical currents in an organ perfusion system |
KR100785656B1 (ko) * | 2007-05-14 | 2007-12-17 | 재단법인서울대학교산학협력재단 | 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체 |
US9770535B2 (en) | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
FR2919785B1 (fr) * | 2007-08-09 | 2017-10-20 | Hemarina Sa | Utilisation d'une globine, d'un protomere de globine ou d'une hemoglobine extracellulaire pour la preservation d'organes, de tissus, ou de cellules d'organes ou de tissus, ou de culture de cellules |
JP5690143B2 (ja) | 2008-02-13 | 2015-03-25 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 持続的細胞プログラミング装置 |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
WO2010128159A1 (en) * | 2009-05-07 | 2010-11-11 | Hemarina | Novel heamoglobin and uses thereof |
US8389474B1 (en) * | 2009-07-14 | 2013-03-05 | Alan Anson Wanderer | Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion |
CA2768552A1 (en) | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
EP2530142B1 (en) * | 2010-01-29 | 2018-03-14 | Organ Technologies Inc. | Perfusion culture method and perfusion culture device for organ or tissue |
CN102770144B (zh) * | 2010-02-23 | 2015-10-07 | 泰尔茂株式会社 | 红血球浓厚液用添加剂以及医疗用容器 |
WO2012048165A2 (en) | 2010-10-06 | 2012-04-12 | President And Fellows Of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
EP2683812A4 (en) * | 2011-03-07 | 2014-12-03 | Massachusetts Inst Technology | METHODS FOR TRANSFECTING CELLS WITH NUCLEIC ACIDS |
NZ616699A (en) | 2011-04-14 | 2016-03-31 | Transmedics Inc | Organ care solution for ex-vivo machine perfusion of donor lungs |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
EP2701745B1 (en) | 2011-04-28 | 2018-07-11 | President and Fellows of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
GB201107466D0 (en) | 2011-05-05 | 2011-06-15 | Loktionov Alexandre | Device and method for non-invasive collection of colorectal mucocellular layer and disease detection |
EP2714073B1 (en) | 2011-06-03 | 2021-03-10 | President and Fellows of Harvard College | In situ antigen-generating cancer vaccine |
SG11201402108YA (en) | 2011-11-11 | 2014-06-27 | Essential Pharmaceuticals Llc | Kit comprising serum replacement and labile factors |
CA2870309C (en) | 2012-04-16 | 2024-02-20 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
CN103461322B (zh) * | 2012-06-07 | 2016-08-03 | 西比曼生物科技(上海)有限公司 | 用于冻存复苏后的细胞的保存液 |
KR101426804B1 (ko) * | 2012-10-09 | 2014-08-05 | 김홍승 | 혈소판 보존 조성물, 이를 포함하는 혈소판 보존 키트 및 이를 이용한 혈소판 보존 방법 |
KR102196974B1 (ko) | 2012-11-30 | 2020-12-31 | 파르마코스모스 에이/에스 | 동결 보호제, 동결 보호 및 동결 보존 조성물, 그 용도 및 동결 보존 방법 |
CN105960165B (zh) * | 2013-11-21 | 2021-03-23 | 李沙丹 | 基于聚合物的移植用保存溶液 |
MX2016008251A (es) * | 2013-12-20 | 2016-10-13 | Essential Pharmaceuticals Llc | Medios para cultivo celular. |
PL3639828T3 (pl) | 2013-12-24 | 2022-05-02 | Virginia Commonwealth University | Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby |
CN103931607A (zh) * | 2014-04-04 | 2014-07-23 | 湖南苗王生物科技有限公司 | 一种鲟鱼精子玻璃化冷冻方法 |
US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
IL303658B1 (en) | 2014-06-02 | 2024-03-01 | Transmedics Inc | Extracorporeal system for organ treatment |
KR101668743B1 (ko) * | 2014-08-08 | 2016-10-25 | (주)세포바이오 | 식물 유래 재조합 인간 혈청 알부민 및 식물성 펩타이드를 유효성분으로 함유하는 세포 보존용 조성물 |
AU2015361996B2 (en) | 2014-12-12 | 2019-09-26 | Transmedics, Inc. | Apparatus and method for organ perfusion |
WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
US11150242B2 (en) | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
AU2016287453A1 (en) * | 2015-06-30 | 2017-09-28 | Société des Produits Nestlé S.A. | Composition suitable for protecting microorganisms |
CN105284786B (zh) * | 2015-10-15 | 2017-12-05 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞保存液及其在保护巨核祖细胞活力中的应用 |
AU2017207707B2 (en) * | 2016-01-14 | 2020-12-17 | DePuy Synthes Products, Inc. | Composition and methods for cryopreservation of hUTC |
CN115531609A (zh) | 2016-02-06 | 2022-12-30 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
CN108450459A (zh) * | 2016-03-06 | 2018-08-28 | 李倩 | 一种人脂肪干细胞用的细胞冻存液 |
CN115305229A (zh) | 2016-07-13 | 2022-11-08 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
CN106613148A (zh) * | 2016-11-19 | 2017-05-10 | 蚌埠市涂山村富民石榴专业合作社 | 一种大棚蒜黄多次采收的种植方法 |
CN106689115A (zh) * | 2016-11-30 | 2017-05-24 | 广州赛莱拉干细胞科技股份有限公司 | 一种脐带保存液及其应用 |
CN106434532A (zh) * | 2016-12-22 | 2017-02-22 | 叶宗耀 | 一种培养肝细胞的培养基及其制备方法 |
CN106857501B (zh) * | 2017-02-22 | 2021-09-24 | 单纯 | 用于保存大鼠肝匀浆s9的储存液及其制备方法 |
CN107041362B (zh) * | 2017-05-23 | 2020-12-22 | 天晴干细胞股份有限公司 | 一种肿瘤组织块深低温冷冻方法 |
CN107624753A (zh) * | 2017-09-19 | 2018-01-26 | 北京瑞格瑞特生物科技有限公司 | 一种细胞低氧稳压运输方法 |
EP3740211A4 (en) | 2018-01-18 | 2021-04-14 | Endoprotech, Inc | TREATMENT OF MICROVASCULAR DISORDERS |
CA3129732A1 (en) * | 2019-02-14 | 2020-08-20 | North Grove Investments, Inc. | Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof |
CN110012901B (zh) * | 2019-04-12 | 2021-06-01 | 西北农林科技大学 | 一种用于猪精液常温保存的稀释制剂 |
KR102344674B1 (ko) * | 2019-06-19 | 2021-12-29 | 가천대학교 산학협력단 | 8-옥소-2'-디옥시구아노신을 유효성분으로 포함하는 이식용 장기의 보존 시 장기손상 방지용 조성물 |
US20230189790A1 (en) * | 2019-11-08 | 2023-06-22 | Bioverde Inc. | Non-freezing refrigerated storage liquid for stem cells |
WO2021173535A1 (en) | 2020-02-26 | 2021-09-02 | Finless Foods Inc. | Systems and methods for live fish tissue preservation |
CN112514892B (zh) * | 2020-12-25 | 2022-06-14 | 广州赛莱拉干细胞科技股份有限公司 | 一种外泌体冻存保护液及其制备方法 |
WO2023023309A1 (en) | 2021-08-20 | 2023-02-23 | Finless Foods Inc. | Systems and methods for fish tissue preservation |
CN113973808A (zh) * | 2021-11-15 | 2022-01-28 | 深圳市人民医院 | 一种改进的细胞冻存液配方 |
CN114600872A (zh) * | 2022-04-13 | 2022-06-10 | 西安北光医学生物技术有限公司 | 一种细胞、组织或器官的抗损伤保存的方法及保存系统 |
CN114698630B (zh) * | 2022-06-06 | 2022-08-23 | 天津百恩生物科技有限公司 | 一种胎盘组织保存液及其制备方法与应用 |
CN115349514B (zh) * | 2022-07-08 | 2024-02-27 | 杭州联川生物技术股份有限公司 | 一种新鲜组织冻存液及其制备方法和应用 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1A (en) * | 1836-07-13 | John Ruggles | Locomotive steam-engine for rail and other roads | |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
JPS57194787A (en) * | 1981-05-28 | 1982-11-30 | Ajinomoto Co Inc | Culture medium for animal cell |
JPS5863385A (ja) * | 1981-10-02 | 1983-04-15 | ハナ・バイオロジツクス・インコ−ポレ−テツド | 免疫系由来の細胞用培地 |
US4657866A (en) * | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
DE3586844T2 (de) | 1984-06-22 | 1994-03-17 | Richard L Veech | Elektrolytlösungen und deren (in vivo) verwendung. |
US4761288A (en) * | 1984-09-24 | 1988-08-02 | Mezei Associates Limited | Multiphase liposomal drug delivery system |
US4879283A (en) | 1985-10-03 | 1989-11-07 | Wisconsin Alumni Research Foundation | Solution for the preservation of organs |
US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
EP0283942B1 (en) * | 1987-03-24 | 1992-05-20 | W.R. Grace & Co.-Conn. | Basal nutrient medium for cell culture |
ATE159287T1 (de) * | 1987-07-24 | 1997-11-15 | Chiron Corp | Lipidmikroemulsionen für wachstumsmedien |
US5061481A (en) | 1989-03-20 | 1991-10-29 | Kobayashi Kose Co., Ltd. | Cosmetic composition having acryl-silicone graft copolymer |
CA2018228C (en) * | 1989-06-05 | 1996-02-27 | Nancy L. Parenteau | Cell culture systems and media |
JPH03180176A (ja) * | 1989-11-16 | 1991-08-06 | W R Grace & Co | 細胞培養のための基礎栄養培地 |
US5066578A (en) | 1989-12-21 | 1991-11-19 | The Regents Of The University Of California | Long-term preservation of organs for transplantation |
US5104787A (en) * | 1990-03-05 | 1992-04-14 | Lindstrom Richard L | Method for apparatus for a defined serumfree medical solution useful for corneal preservation |
JPH0728732B2 (ja) * | 1990-04-17 | 1995-04-05 | 日本石油株式会社 | 動物細胞増殖促進剤及び無血清培地 |
JPH0459735A (ja) * | 1990-06-27 | 1992-02-26 | Terumo Corp | ヘモグロビン含有リポソーム |
JP2956998B2 (ja) | 1990-10-11 | 1999-10-04 | テルモ株式会社 | 移植器官潅流保存液および移植器官潅流保存法 |
CA2089653A1 (en) * | 1991-06-17 | 1992-12-18 | Dennis M. Disorbo | Media concentrate technology |
CA2123094C (en) | 1991-11-06 | 1999-08-10 | Paulo N. Correa | Cell culture medium |
US6291424B1 (en) | 1991-11-14 | 2001-09-18 | Brigham And Women's Hospital | Nitrosated and nitrosylated heme proteins |
US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
AU3922193A (en) | 1992-03-23 | 1993-10-21 | Georgetown University | Liposome encapsulated taxol and a method of using the same |
US5370989A (en) | 1992-04-03 | 1994-12-06 | The Trustees Of Columbia University In The City Of New York | Solution for prolonged organ preservation |
US5637315A (en) * | 1993-01-04 | 1997-06-10 | Thomas Jefferson University | Treatment of disease states induced by oxidative stress |
US5599659A (en) | 1993-03-11 | 1997-02-04 | Breonics, Inc. | Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate |
AU6523194A (en) | 1993-03-26 | 1994-10-24 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
US5405742A (en) * | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
AU7560994A (en) | 1993-08-12 | 1995-03-14 | University Of North Carolina At Chapel Hill, The | Rinse solution for organs and tissues |
FR2709666B1 (fr) * | 1993-09-07 | 1995-10-13 | Oreal | Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire. |
US5428039A (en) | 1994-02-20 | 1995-06-27 | The Center For Innovative Technology | Method for electively achieving reversible hyperpolarized cardiac arrest |
US5543316A (en) * | 1994-04-20 | 1996-08-06 | Diacrin, Inc. | Injectable culture medium for maintaining viability of myoblast cells |
US6004579A (en) | 1995-09-14 | 1999-12-21 | Lxr Biotechnology, Inc. | Compositions which inhibit apoptosis, methods of making the compositions and uses thereof |
US5670545A (en) | 1996-02-09 | 1997-09-23 | Board Of Regents Of The University Of Colorado | Method for the treatment of ischemic disease and reperfusion injury and the prevention of the adverse effects of reactive oxygen species |
US5897987A (en) * | 1996-03-25 | 1999-04-27 | Advanced Reproduction Technologies, Inc. | Use of arabinogalactan in cell cryopreservation media |
US5696152A (en) * | 1996-05-07 | 1997-12-09 | Wisconsin Alumni Research Foundation | Taxol composition for use as organ preservation and cardioplegic agents |
US5843024A (en) | 1996-05-17 | 1998-12-01 | Breonics, Inc. | Solution and process for resuscitation and preparation of ischemically damaged tissue |
WO1998013386A1 (en) | 1996-09-27 | 1998-04-02 | The Board Of Trustees Of The University Of Illinois | Oxygen-binding heme proteins incorporating circularly-permuted globins |
US6274305B1 (en) * | 1996-12-19 | 2001-08-14 | Tufts University | Inhibiting proliferation of cancer cells |
US6495532B1 (en) | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
AU751876B2 (en) * | 1997-03-19 | 2002-08-29 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
US6416740B1 (en) * | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US5834178C1 (en) * | 1997-07-09 | 2002-04-23 | Univ Wayne State | Flush-storage solution for donor organs |
US5948609A (en) | 1997-12-03 | 1999-09-07 | Carter; Daniel C. | Oxygen-transporting albumin-based blood replacement composition and blood volume expander |
EP1064353B1 (en) * | 1998-03-18 | 2002-11-06 | Massachusetts Institute Of Technology | Vascularized perfused microtissue/micro-organ arrays |
DE59914485D1 (de) * | 1998-03-30 | 2007-10-18 | Mibelle Ag Cosmetics | Verwendung von Nanoemulsionen zur Bestimmung der Biokompatibilität von lipophilen Stoffen im Zellkultur-Test und dafür geeignete Nanoemulsionen |
JP4222658B2 (ja) * | 1998-06-23 | 2009-02-12 | テルモ株式会社 | 細胞支持基材、培養装置および液体処理装置 |
US6406909B1 (en) * | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
US6204375B1 (en) * | 1998-07-31 | 2001-03-20 | Ambion, Inc. | Methods and reagents for preserving RNA in cell and tissue samples |
US6200590B1 (en) * | 1998-08-10 | 2001-03-13 | Naphcare, Inc. | Controlled, phased-release suppository and its method of production |
US6153582A (en) * | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
US6582953B2 (en) * | 1999-04-14 | 2003-06-24 | Breonics, Inc. | Organ chamber for exsanguinous metabolic support system |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
FR2793495B1 (fr) * | 1999-05-14 | 2001-08-10 | Imv Technologies | Dilueur pour la cryoconservation de spermatozoides de bovins |
US6670184B2 (en) * | 2000-06-23 | 2003-12-30 | Basf Ag | Method for producing a lipid emulsion for use in insect cell culture |
CA2417331C (en) * | 2000-07-28 | 2011-03-22 | Christopher J. Murphy | Transplant media comprising bnp-1 |
US7198895B2 (en) * | 2000-11-14 | 2007-04-03 | Mohanlal Ramon W | In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals |
CN1325046C (zh) * | 2001-08-31 | 2007-07-11 | 麦吉尔大学 | 可生物降解的多聚纳米微囊及其应用 |
EP1475434A1 (en) * | 2003-05-09 | 2004-11-10 | Oncoscience AG | Method for storing tumor cells |
-
2003
- 2003-09-30 EP EP03022146A patent/EP1475434A1/en not_active Withdrawn
-
2004
- 2004-05-07 MX MXPA05012070A patent/MXPA05012070A/es active IP Right Grant
- 2004-05-07 KR KR1020057021228A patent/KR20060019525A/ko not_active Application Discontinuation
- 2004-05-07 AU AU2004239310A patent/AU2004239310B2/en not_active Ceased
- 2004-05-07 EP EP04751778.4A patent/EP1624750B1/en not_active Expired - Lifetime
- 2004-05-07 WO PCT/EP2004/004897 patent/WO2004099393A1/en active Application Filing
- 2004-05-07 CN CN2004800189342A patent/CN1816617B/zh not_active Expired - Fee Related
- 2004-05-07 CN CNA2004800125711A patent/CN1784142A/zh active Pending
- 2004-05-07 AU AU2004236402A patent/AU2004236402B2/en not_active Ceased
- 2004-05-07 RU RU2005138320/15A patent/RU2005138320A/ru not_active Application Discontinuation
- 2004-05-07 CA CA2523417A patent/CA2523417C/en not_active Expired - Fee Related
- 2004-05-07 US US10/556,083 patent/US7604933B2/en not_active Expired - Fee Related
- 2004-05-07 CA CA2526933A patent/CA2526933C/en not_active Expired - Fee Related
- 2004-05-07 EP EP04731585A patent/EP1623021A1/en not_active Withdrawn
- 2004-05-07 JP JP2006532912A patent/JP5192694B2/ja not_active Expired - Fee Related
- 2004-05-07 WO PCT/US2004/014551 patent/WO2004101758A2/en active Application Filing
- 2004-05-07 BR BRPI0410185-5A patent/BRPI0410185A/pt not_active IP Right Cessation
- 2004-05-07 JP JP2006505398A patent/JP4870551B2/ja not_active Expired - Fee Related
- 2004-05-07 US US10/841,756 patent/US7220538B2/en not_active Expired - Lifetime
-
2005
- 2005-12-01 ZA ZA200509760A patent/ZA200509760B/xx unknown
-
2007
- 2007-03-22 US US11/689,876 patent/US7537885B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2004101758A2 (en) | 2004-11-25 |
US7604933B2 (en) | 2009-10-20 |
US20070178435A1 (en) | 2007-08-02 |
EP1624750A2 (en) | 2006-02-15 |
EP1475434A1 (en) | 2004-11-10 |
US7537885B2 (en) | 2009-05-26 |
CN1816617A (zh) | 2006-08-09 |
JP5192694B2 (ja) | 2013-05-08 |
AU2004236402B2 (en) | 2009-12-03 |
AU2004239310B2 (en) | 2010-06-17 |
AU2004239310A1 (en) | 2004-11-25 |
US7220538B2 (en) | 2007-05-22 |
JP2007524368A (ja) | 2007-08-30 |
KR20060019525A (ko) | 2006-03-03 |
CA2526933C (en) | 2013-02-12 |
EP1624750B1 (en) | 2015-12-30 |
JP2007502130A (ja) | 2007-02-08 |
CA2526933A1 (en) | 2004-11-25 |
US20050037330A1 (en) | 2005-02-17 |
CN1816617B (zh) | 2010-12-01 |
EP1624750A4 (en) | 2006-10-25 |
JP4870551B2 (ja) | 2012-02-08 |
AU2004236402A1 (en) | 2004-11-18 |
MXPA05012070A (es) | 2006-06-23 |
WO2004099393A1 (en) | 2004-11-18 |
BRPI0410185A (pt) | 2006-05-16 |
WO2004101758A3 (en) | 2005-08-11 |
CN1784142A (zh) | 2006-06-07 |
CA2523417A1 (en) | 2004-11-18 |
ZA200509760B (en) | 2006-11-29 |
CA2523417C (en) | 2013-04-30 |
EP1623021A1 (en) | 2006-02-08 |
US20070042338A1 (en) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005138320A (ru) | Композиция для поддержания жизнеспособности органов и клеток | |
JP3859708B2 (ja) | 表皮細胞用の培養培地として使用される栄養培地と適用 | |
Millán et al. | Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis | |
KR20080110589A (ko) | 세포 에너지 직접 전달 시스템 | |
US20120052136A1 (en) | Novel heamoglobin and uses thereof | |
NZ537163A (en) | A direct cellular energy delivery system | |
Estrela et al. | Regulation of glutathione metabolism in Ehrlich ascites tumour cells | |
US5047395A (en) | Reduction of oxyradical damage in biomedical applications | |
US20210368780A1 (en) | Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof | |
CN100435793C (zh) | 包含谷胱甘肽代谢之效应子及α-硫辛酸的肾替代疗法用药物 | |
EP3592840B1 (en) | Culture medium comprising dipeptides | |
JPH1146759A (ja) | 細胞培養液 | |
CN117940556A (zh) | 包含二肽和微量元素的组合物 | |
EP4346402A1 (en) | Compositions and methods for lung preservation | |
FR2729076A1 (fr) | Milieu nutritif utilisable comme milieu de culture de cellules epidermiques et base nutritive a usage topique | |
BR122023002098B1 (pt) | Métodos para preparar vasos sanguíneos personalizados | |
FR2846005A1 (fr) | Composition pour milieu biologique comprenant de l'erythorbate de sodium | |
JP2001510996A (ja) | 臓器培養内角膜の脱水用試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090212 |